Navigation Links
Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
Date:7/14/2009

g these, approximately 2,300 children and adolescents die of cancer each year making cancer the most common cause of disease-related mortality for children 1 to 19 years of age. (NCI SEER Data) There are 12 major types of childhood cancers, and of these leukemias, brain and other central nervous system tumors (ie, gliomas and medulloblastomas) account for over 50% of the new cases. The remainder of new cases include extracranial tumors such as neuroblastomas, Wilms tumors, and rhabdomyosarcomas. Although improvements in imaging equipment and treatments have resulted in an overall decline in mortality and increased survival, approximately half of all children with malignant solid tumors will experience relapse and, of these children, less than 10% will achieve long-term survival after standard multimodal therapy.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM)(ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also actively engages in
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... YORK , Sept. 18, 2014 This BCC Research ... share of major players, market growth and size, and opportunities ... trends and revenue through 2018. Patent analysis in the report ... as the U.S., Europe and ... to: - Define and discuss the global medical device technologies ...
(Date:9/18/2014)... Sept. 18, 2014   Fruit Street Health ... initial seed round of funding. The ... by a series of individual investors, the majority of ... in the initial round are; Houston Cardiology Consultants ... Urologist Stacy Childs, Rapha Family Medicine Practice Owner ...
(Date:9/18/2014)... 2014  ADM Tronics Unlimited, Inc. (OTCQB: ADMT) ... its corporate Advisory Board for business development. ... Harvard Medical School and Visiting Professor at the ... Masters degree in Electronics Engineering and his Ph.D. ... Bologna. After spending a year as a visiting ...
Breaking Medicine Technology:Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3
... ADDISON, Texas, March 11, 2011 U LURUInc.(NYSE ... the development of a portfolio of wound management and oral ... NYSE Amex LLC (the "Exchange") advising ULURU that it is ... continued listing standards under Section 1003 of the Exchange,s Company ...
... (Nasdaq: NVAX ), a clinical-stage vaccine company, announced ... be presenting at the ROTH 23rd Annual OC Growth Stock ... at The Ritz Carlton, Laguna Niguel, CA.  A live audio-only ... Company website at www.novavax.com under Investors/Events, and a ...
Cached Medicine Technology:ULURU Inc. Receives Letter of Non-Compliance From NYSE Amex 2
(Date:9/19/2014)... September 19, 2014 A McLean ... Circuit Court (case 14-L-1175), following a failed hip replacement ... is suing DePuy Orthopaedics Inc. and Johnson & Johnson ... Flood Law Group, a nationally known personal injury law ... following developments in litigation involving defective hips. , According ...
(Date:9/19/2014)... together with friends is a big part of being young, ... to look graceful without spending a large sum of money. ... fashionable prom dresses. Apart from this, it has launched a ... Now, all the global consumers can enjoy a discount, up ... , The company’s chief executive officer says, “We are ...
(Date:9/18/2014)... (PRWEB) September 19, 2014 When Mary Ann Thompson ... the couple, who live in Bali, Indonesia with their son, Isaac, ... The two met at Mercy College in 2001 when Thompson ... Nikel, who was a graduate student at the time, was French ... from Jamaica and migrated to the United States when she was ...
(Date:9/18/2014)... cancer experts around the world have issued a plea ... carry out high quality research and clinical trials for ... fatal and for which there are many unanswered questions. ... management of advanced breast cancer, published simultaneously in the ... Annals of Oncology [1] today (Friday), the experts ...
(Date:9/18/2014)... 2014 A jacket is a hip- ... typically has sleeves, and fastens in the front or ... tighter-fitting, and less insulating than a coat, which is ... protective clothing. Today, Fecbek, a well-known clothing manufacturer and ... men’s jackets; all these items are offered at extremely ...
Breaking Medicine News(10 mins):Health News:Flood Law Group Comments on Recent Hip Replacement Lawsuit 2Health News:With New Semester Under Way, LunaDress Unveils The Most Fashionable Prom Dresses 2Health News:For The First Time in Over a Decade Mercy College Alumni Marry at College 2Health News:Experts issue plea for better research and education for advanced breast cancer 2Health News:Experts issue plea for better research and education for advanced breast cancer 3Health News:Experts issue plea for better research and education for advanced breast cancer 4Health News:Experts issue plea for better research and education for advanced breast cancer 5Health News:Cool Jackets Are For Sale At Fecbek.com 2
... Over 50% of the teenagers who suffer from eating disorders do ... may even be for over six months. As many as 1,000 ... said that they are capable of recognizing such disorders in their ... noticed by their parents. ,The research was conducted ...
... Geneva University Hospital, tested the new technique of methicillin-resistant ... ,He said that it could reduce // ... the money spent in order to deal with these ... bacteria DNA in the patient swabs. ,This ...
... researchers at Washington University has highlighted a new combination ... treatment modality claims to even restore normal breathing in ... models have revealed promising findings, the results of which ... The dual drug combination is believed to enhance airway ...
... Custom officials in Hong Kong have been put on high ... among birds and poultry. // The officials have been instructed ... and poultry into the territory. ,The proposed move ... trafficking of birds. The health chief of the former British ...
... Health Foundation, even as the UK seeks to win the football World ... out how much importance men give to the game. Evaluations will be ... their jobs just for the pleasure of watching the game, and as ... or participate in the game itself. ,The Health Charity ...
... a common gene which gives rise to Alzheimer's disease, according ... Medicine. This could also serve to conclusively prove that it ... 1,000 families in which the Alzheimer's disease is prevalent in ... with regard to the disease was sought to be established ...
Cached Medicine News:Health News:Eating Disorders Among Children Are Widespread 2Health News:Bird Flu Threat Prompts Tightened Security Across Hong Kong Border 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: